AbbVie wants USITC to investigate Alvotech over Humira ‘theft’

AbbVie seeks to block imports of Alvotech’s biosimilar Humira (adalimumab) into the US, claiming that the Icelandic company plundered former employees and used its trade secrets to develop the drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

AbbVie and Alvotech settle all US Humira litigation

10 March 2022 AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).

Biotechnology

ITC to investigate Alvotech’s Humira biosimilar

27 January 2022 The US International Trade Commission will investigate whether drug manufacturers used trade secrets to develop a biosimilar of AbbVie’s Humira.

Biotechnology

Illinois court rejects dismissal of AbbVie patent case

26 August 2021 The US District Court for the Northern District of Illinois has refused to dismiss a lawsuit from AbbVie which alleges Icelandic pharmaceutical company Alvotech infringed patents related to its arthritis drug Humira.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

AbbVie wants USITC to investigate Alvotech over Humira ‘theft’

More on this story

Editor's picks

Editor's picks

More features